The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) was $7.15 for the day, down -2.46% from the previous closing price of $7.33. In other words, the price has decreased by -$2.46 from its previous closing price. On the day, 3.69 million shares were traded. BCRX stock price reached its highest trading level at $7.465 during the session, while it also had its lowest trading level at $7.14.
Ratios:
Our analysis of BCRX’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.76 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 96.83. For the most recent quarter (mrq), Quick Ratio is recorded 2.22 and its Current Ratio is at 2.25.
On April 29, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $20.
On February 25, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $15.Wedbush initiated its Outperform rating on February 25, 2025, with a $15 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 13 ’25 when HEGGIE THERESA sold 70,000 shares for $8.51 per share. The transaction valued at 595,868 led to the insider holds 65,352 shares of the business.
HEGGIE THERESA bought 70,000 shares of BCRX for $595,871 on Aug 13 ’25. On Dec 13 ’24, another insider, Hutson Nancy J, who serves as the Director of the company, sold 7,000 shares for $7.54 each. As a result, the insider received 52,780 and left with 86,638 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCRX now has a Market Capitalization of 1500931072 and an Enterprise Value of 1979810048. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.69. Its current Enterprise Value per Revenue stands at 3.551 whereas that against EBITDA is 33.839.
Stock Price History:
The Beta on a monthly basis for BCRX is 1.09, which has changed by -0.038978517 over the last 52 weeks, in comparison to a change of 0.17904854 over the same period for the S&P500. Over the past 52 weeks, BCRX has reached a high of $11.31, while it has fallen to a 52-week low of $6.01. The 50-Day Moving Average of the stock is -11.87%, while the 200-Day Moving Average is calculated to be -15.85%.
Shares Statistics:
BCRX traded an average of 2.92M shares per day over the past three months and 2712090 shares per day over the past ten days. A total of 209.91M shares are outstanding, with a floating share count of 195.19M. Insiders hold about 3.44% of the company’s shares, while institutions hold 93.52% stake in the company. Shares short for BCRX as of 1757894400 were 28316467 with a Short Ratio of 9.69, compared to 1755216000 on 27082099. Therefore, it implies a Short% of Shares Outstanding of 28316467 and a Short% of Float of 13.54.
Earnings Estimates
Current recommendations for the stock of the company come from 4.0 analysts. The consensus estimate for the next quarter is $0.03, with high estimates of $0.04 and low estimates of $0.02.
Analysts are recommending an EPS of between $0.36 and $0.06 for the fiscal current year, implying an average EPS of $0.18. EPS for the following year is $0.47, with 4.0 analysts recommending between $0.8 and $0.31.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 9 analysts. It ranges from a high estimate of $166.22M to a low estimate of $160.15M. As of. The current estimate, Biocryst Pharmaceuticals Inc’s year-ago sales were $117.08MFor the next quarter, 9 analysts are estimating revenue of $154.51M. There is a high estimate of $162.08M for the next quarter, whereas the lowest estimate is $147.98M.
A total of 10 analysts have provided revenue estimates for BCRX’s current fiscal year. The highest revenue estimate was $631.12M, while the lowest revenue estimate was $620.55M, resulting in an average revenue estimate of $626.53M. In the same quarter a year ago, actual revenue was $450.71MBased on 10 analysts’ estimates, the company’s revenue will be $657.2M in the next fiscal year. The high estimate is $702M and the low estimate is $608M.
